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Abstract A key objective in two phase 2b AMP clinical trials of VRC01 is to eval-
uate whether drug concentration over time, as estimated by non-linear mixed effects
pharmacokinetics (PK) models, is associated with HIV infection rate. We conducted
a simulation study of marker sampling designs, and evaluated the effect of study ad-
herence and sub-cohort sample size on PK model estimates in multiple-dose studies.
With m = 120, even under low adherence (about half of study visits missing per
participant), reasonably unbiased and consistent estimates of most fixed and random
effect terms were obtained. Coarsened marker sampling schedules were also studied.
keywords: multiple-dose; NONMEM; population PK analysis; simulation-based
sampling design; study adherence; two-compartment PK model.
1 Introduction
VRC01 is a human IgG1 broadly neutralizing monoclonal antibody (mAb) directed
against the CD4-binding site of HIV-1 ([1–5]). In 2016, the HIV Vaccine Trials Net-
work and HIV Prevention Trials Network launched the VRC01 Antibody Mediated
Prevention (AMP) study, the first efficacy study of a broadly neutralizing anti-HIV
antibody for prevention of HIV infection. The study is being conducted in two har-
monized trials in two cohorts: 2700 HIV-uninfected men and transgender persons in
the Americas and Switzerland; and 1500 HIV-uninfected sexually active women in
sub-Saharan Africa ([6]). Within each cohort, AMP participants are randomized to
receive 10 IV infusions of 10 mg/kg VRC01, 30 mg/kg VRC01, or placebo every 8
weeks through 72 weeks. Besides the evaluation of prevention efficacy of VRC01, an
important secondary objective of AMP is to assess VRC01 mAb markers, e.g. serum
mAb concentrations over time, as correlates of protection (CoP) against HIV-1 infec-
tion. This knowledge is anticipated to help guide further development of mAbs and
to provide benchmarks for HIV-1 vaccine development.
In the AMP correlates study, a case-control sampling design is used. Markers are
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measured from primary endpoint HIV-1 infected cases in the mAb groups and from
a random sample of control participants from each mAb group who remain HIV-1
negative until at least the Week 80 study visit ([6]). While complete pharmacokinetics
(PK) information (e.g. concentration at any given time) is desirable especially in the
study of time-dependent correlates, it is infeasible to sample continuously or on an
intensive time scale. Therefore, the full trajectory of VRC01 concentrations over time
needs to be estimated based on the concentration data collected at selected time-points
for the correlates study. As specified in the AMP protocol, 4-weekly blood samples
were draw for possible marker measurements at up to 22 visits prior to Week 80 (i.e.,
4 weeks and 8 weeks [trough] after each 8-weekly infusion), and at the visit scheduled
5 days after the second infusion (Figure 1). Of note, in the real trials these sampling
times are subject to variations as a result of imperfect study adherence due to possible
missed visits, permanent infusion discontinuations and study dropout, and actual visit
windows around each target visit date (Supplementary materials). Therefore, besides
different marker sampling designs, we also consider different levels of study adherence
and their impact on the outcomes in the simulations described herein.
In this paper, we focus on the modeling of VRC01 concentrations among hypotheti-
cal HIV-uninfected control participants in AMP, defined as participants assigned to a
VRC01 group who reach the Week 80 visit HIV-1 negative. Because all AMP partic-
ipants acquiring HIV-1 infection during the study are sampled for measuring VRC01
concentrations at all available sampling time-points, the relevant sampling question
is how many control participants and what time-points to sample in the AMP corre-
lates study. Besides a range of sample sizes of control participants, we consider time-
point sampling according to: 1) the complete schedule of all 22 possible visits; and 2)
coarsened schedules of only a subset of visits. In addition, because mAb serum con-
centrations often change non-linearly over time with possible individual-to-individual
variability, population PK (popPK) analysis based on non-linear mixed effects models
is used to estimate population and individual PK parameters, as well as to estimate
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individual-level serum concentrations over time (with associated estimation uncertain-
ties) that can be assessed as potential correlates.
The outline of this paper is as follows. In Section 2, we introduce the Master PK model
that is used for the simulation of AMP participants’ serum concentration data; the
simulation set-up, including different marker sampling designs for the AMP control
cohort; and the method for estimating PK model parameters based on the simulated
datasets. In Section 3, we compare the performance of different complete and coarsened
schedule marker sampling designs in terms of the accuracy and precision of the PK
parameter estimates. We draw some conclusions and recommendations in Section 4.
2 Methods
2.1 Master PK model
A two-compartment model is deemed fitting to describe the PK of VRC01, since this
mAb has limited distribution volume, slow clearance, and hence a long half-life (∼15
days). Non-linear mixed effects models are used to describe individual-to-individual
processes of drug absorption, distribution, and elimination and how these vary across
individuals of different characteristics (e.g. weight, sex, or age). We use the popPK
model that best describes the serum concentration data collected in a phase 1 study
of VRC01 [7] as the prototype Master model for the simulation of concentration data
from AMP participants. In the following, we briefly review the Master popPK model
with two levels: the individual-level PK (or structure) model, which describes the
intra-individual patterns of serum concentration over time through the processes of
drug absorption, distribution, and elimination; and the population-level (or variability)
model, which describes the inter-individual variability of the processes.
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2.1.1 Individual-level PK model
et S(tij) denote the VRC01 serum concentration at the j
th measurement for subject
i. In the Master individual-level PK model, it is defined as
S(tij) = f(tij, Di, βi) ∗ (1 + e1ij) + e2ij, for i = 1, . . . ,m, j = 1, . . . ,mi
where f denotes a two-compartment model with dose Di, βi = (CLi, Vci , Vpi , Qi) de-
notes parameters of f specific to individual i, and the proportional error and ad-
ditive constant error terms e1ij and e2ij satisfy, respectively, E(e1ij|Di, βi) = 0,
var(e1ij|Di, βi) = σ21 and E(e2ij|Di, βi) = 0, var(e2ij|Di, βi) = σ22. There are dif-
ferent ways of parameterizing a compartment model. For their direct physiology sig-
nificance, CL: clearance rate (L/day), Vc: volume of distribution in the central com-
partment (L), Vp: volume of distribution in the peripheral compartment (L), and Q:
inter-compartmental clearance (L/day) are often a set of parameters used to describe
PK processes underlying the observed concentration profiles for a given subject under
a two-compartment model.
Specifically, after a single IV infusion, the serum drug concentration at time t (relative
to the end of infusion) can be expressed as the sum of two exponential processes –
distribution and elimination (i.e. a two-compartment model):
S(t) =
D
Tinf
[
A
α
(1− e−αTinf )e−αt + B
β
(1− e−βTinf )e−βt
]
where D = IV dose amount (mg); Tinf = duration of infusion; α and β are rate
constants (slopes) for the distribution phase and elimination phase, respectively (α > β
by definition); and A and B are intercepts on the y axis for each exponential segment
of the curve. Of note, when αTinf → 0 and βTinf → 0 [as is the case for IV bolus
administrations and is approximately the case for IV VRC01, where the infusion time
is brief (∼30 minutes) relative to the half-life], S(t) = D[Ae−αt + Be−βt] because
limh→0 e
h−1
h
= 1. Let k12 = Q/Vc and k21 = Q/Vp represent the first-order rate
transfer constants (1/day) for the movement of drug between the central and peripheral
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compartments. Mathematically, α and β relate to the rate constants k12 and k21 as
α + β = k12 + k21 + k and αβ = k21k, where k =
CL
Vc
= αβ(A+B)
Aβ+Bα
is the rate of drug
elimination. In addition, A = α−k21
Vc(α−β) and B =
k21−β
Vc(α−β) . After multiple doses, serum
drug concentration at time t after k doses Dj (j = 1, . . . . , k) given at time tDj(t ≥ tDk)
can then be expressed as written below, based on the superimposed assumption that
the PK of the drug after a single dose are not altered after taking multiple doses:
S(t) =
k∑
j=1
Dj(Ae
−α(t−tDj ) +Be−β(t−tDj ))
2.1.2 Population PK model
Let βi = d(ai, β, bi), for i = 1, . . . ,m where d denotes a p-dimensional function, ai
denotes a vector of characteristics for subject i that contribute to explaining inter-
individual variability, β denotes fixed effects, and bi denotes random effects. This
equation characterizes how elements of βi vary across individuals due to systematic
association with ai (modeled via β) and unexplained variation in the population repre-
sented by bi. The usual assumptions E(bi|ai) = E(bi) = 0 and var(bi|ai) = var(bi) = Ω
are implied.
In the Master population-level PK model, all four individual-level PK parameters are
modeled as log-normally distributed with exponential inter-individual variability (IIV)
random effects. Let CLi, Vci , Qi, and Vpi denote individual-level estimated CL, Vc, Q,
and Vp, respectively, for individual i. Covariates ai include only BWi, body weight of
subject i, which has an influence on CLi and Vci via an exponential model as follows:
CLi = βCL ∗ exp(βBW.CL ∗ (BWi − 74.5)) ∗ exp(bCLi)
Vci = βVc ∗ exp(βBW.Vc ∗ (BWi − 74.5)) ∗ exp(bVci )
Qi = βQ ∗ exp(bQi)
Vpi = βVp ∗ exp(bVpi )
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2.2 Simulation set-up
2.2.1 Study adherence
Each participant’s infusion and post-infusion visit schedule is simulated according to
the AMP protocol specification (Supplementary Materials). Briefly, participants re-
ceive 10 IV infusions of VRC01 (or placebo). Each infusion visit has a visit window of
-7 to +48 days around the scheduled 8-weekly infusion visit target date. Participants’
marker measurements occur at each infusion visit, 4 weeks (visit window: -7 to +7
days) after each infusion, and 5 days (-2 to +2 days) after the second infusion. In the
following simulations, for infusion visits, we assume that 80% of the attended visits
occur uniformly during the target window of -7 to +7 days and 20% during the allow-
able window of +7 to +48 days. For post-infusion visits that occur between infusion
visits, we assume all attended visits occur uniformly during the specified window.
Overall, we consider four study adherence patterns defined by the combinations of four
missing data probabilities: probability of an independently missed single infusion (p1),
probability of an independently missed post-infusion visit (p2), cumulative probability
of permanent infusion discontinuation (r1), and annual dropout rate (r2). The four
study adherence patterns in terms of (p1, p2, r1, r2) are: perfect adherence = (0%,
0%, 0%, 0%), high adherence = (5%, 10%, 10%, 10%), medium adherence = (10%,
15%, 15%, 15%), and low adherence = (15%, 20%, 20%, 20%). At 1 year after trial
initiation, the adherence is very high in the ongoing AMP study with rates of (2%, 3%,
5%, 5%). Nevertheless, a wider range of adherence levels are considered in this paper
for interpolation purposes and for investigating the robustness of popPK modeling
against missing data, relevant if adherence declines in AMP or for future mAb studies.
2.2.2 PK model parameter values
Once participants’ infusion and post-infusion visits are simulated according to the
study adherence patterns described above, the Master popPK model described in
section 2.1 is used to simulate VRC01 serum concentration at attended study visits
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for participants of a given body weight in each VRC01 dose group (10 mg/Kg and 30
mg/Kg). The PK parameter values used for the simulation are listed in Table 1, where
low covariances between random effects are fixed at zero to increase model stability.
2.2.3 Computation software
R version 3.3.1 [8] was used for the simulation of participants’ characteristics and
study visit data. The NONMEM software system (Version 7.3, ICON Development
Solutions) was used for the simulation and modeling of concentration data. Parallel
computing on eight central processing units was employed to speed up computation
time via NONMEM.
2.2.4 Marker sampling design
We consider two types of marker sampling designs: complete schedule and coarsened
schedule (Figure 2). The former design includes concentration data at all time-points
of visit attendance from each participant, whereas the latter includes concentration
data only at a subset of time-points. Because a total of 61 VRC01 HIV-infected
cases are expected at 60% prevention efficacy for both dose groups pooled over both
AMP trials, for the complete schedule design, we consider sample sizes of m = 30, 60,
120, and 240 HIV-1 uninfected controls. The latter three sample sizes correspond to
the numbers of expected controls in the case-control cohort with a 1:1, 1:2, and 1:4
case:control ratio, respectively, whereas m = 30 serves as a reference and represents
the 1:1 case:control ratio for a single AMP trial. For the coarsened schedule design,
we consider only one sample size of m=240, but 3 coarsened schedules that sample
roughly half of the complete schedule time-points per participant.
• First half: the first 11 time-points (excluding time 0) out of the total 22 complete
schedule time-points are sampled. These time-points include, for every individ-
ual the 4-week and 8-week post-infusion time-points (trough) after the first 5
infusions, in addition to the 5-day time-point after the 2nd infusion.
• Mixed half: time-points after every other infusion are sampled. In addition to
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the 5-day time-point after the 2nd infusion for every individual, 4-week and 8-
week time-points (trough) after the five odd number (1st, 3rd, 5th, 7th, and 9th)
infusions are included for one half of the subjects (m = 120), and 4-week and
8-week post-infusion time-points after the five even number (2nd, 4th, 6th, 8th,
and 10th) infusions are included for the other half of the subjects (m = 120).
• Trough only: trough time-points are sampled. These include, for every individual
the 8-week time-points (trough) after each of the 10 infusions, in addition to the
5-day time-point after the 2nd infusion.
Note that for all 3 coarsened schedules, the 5-day time-point after the 2nd infusion is
always included because this time-point is the only one scheduled within a few days of
an infusion for the estimation of Vc. These 3 coarsened schedules are compared to the
complete schedule with m = 120, since the same number of 4-week and 8-week post
infusion observations are made.
2.2.5 Simulation steps
For the complete schedule marker sampling design, we consider a total of 16 scenarios
representing combinations of 4 study adherence patterns (perfect, high, medium, and
low) and 4 sample sizes (m=30, 60, 120, and 240). For the coarsened schedule marker
design, we consider a total of 12 scenarios representing the combinations of 4 study ad-
herence patterns and 3 coarsened schedules (First half, Mixed half, and Trough only).
The complete schedule datasets with m=240 are first simulated and the coarsened
schedule datasets are extracted from them given the specific design. For each sce-
nario, 1000 datasets are simulated containing participants’ demographic information
(body weight and sex), study information (infusion and post-infusion visit time), and
serum concentration at attended visits. Depending on the research interest, concen-
tration values on consecutive days or flexible grid can also be simulated to evaluate the
modeling/prediction of simulated concentration using sparse data. Specifically, each
dataset is simulated following the steps described below:
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Step 1: Simulate participants’ characteristics representing the two AMP study cohorts
and their corresponding VRC01 dose amounts in the low and high dose groups.
a. Simulate 1:1 male:female sex ratio.
b. For females and males, respectively, randomly sample participants’ body
weight with replacement from females in the Phambili trial in South Africa
[10], and from males in the Step study in the Americas [11]. Participants’
body weights are assumed to be constant throughout the trial.
c. Within each sex, participants are randomly assigned to the 10 mg/Kg and
30 mg/Kg dose groups at a 1:1 ratio. Each participant’s VRC01 dose
amount is determined as the product of his/her body weight and dose level.
Step 2: Simulate participants’ 8-weekly infusion visits.
a. Simulate the attendance (yes or no) of each of the 10 infusion visits using
a Bernoulli probability of p1.
b. If attendance is ‘yes’ for a given infusion visit, simulate the infusion visit
time according to the AMP protocol-specified schedules and visit windows,
assuming the probability of attending the visit within the target window
(typically -7 to +7 days) is 80% and the probability of attending the visit
outside the target window but within the study allowable window (typically
-7 to +48 days) is 20%. The infusion time follows a piece-wise uniform
distribution within and outside the target window.
Step 3: Simulate participants’ post-infusion visits: baseline, 4-weekly, and 5-day post-2nd
infusion.
a. Simulate post-infusion visit attendance (yes or no) according to prior in-
fusion attendance. If the prior infusion is administered, simulate the visit
attendance using a Bernoulli probability of p2. If the prior infusion is missed,
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then the 5-day post-2nd infusion visit (if applicable) and the following 4-
week post-infusion visits are all considered missed. If the last infusion (#10)
is missed, then the 4-week post-infusion visit is also missed. However, the
8-week post infusion visit could still be scheduled.
b. If post-infusion attendance is ‘yes’, simulate post-infusion visit time ac-
counting for prior infusion visit time, according to protocol-specified sched-
ules/windows, similar to the procedure described in Step 2b.
Step 4: Modify infusion attendance and post-infusion visits accounting for permanent
infusion discontinuation.
– Simulate time to permanent infusion discontinuation (due to reasons other
than HIV infection) using a random exponent rate r1.
– Modify infusion attendance and post-infusion visits for those who discon-
tinue infusion permanently according to a different protocol-specified visit
schedule/window (Supplementary Materials).
Step 5: Modify infusion attendance and post-infusion visits accounting for dropout (study
termination).
– Simulate time to dropout using a random exponent rate r2.
– Censor all previously simulated infusion and post-infusion visits at dropout
time.
Step 6: Simulate participants’ concentrations according to the Master PK model, with
the covariate information, dose amount, infusion, and visit schedules as in the
previous steps.
(a) Simulate S(tij) according to the final PK model by setting bi = 0 and
ij = 0.
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(b) Add the above value to a mean-zero normally distributed bi and ij, accord-
ing to the variance estimates from the final PK model.
2.3 Estimation Method
Parameter estimation of the popPK model is based on minimizing the objective func-
tion value using maximum likelihood estimation. A marginal likelihood of the observed
data is calculated based on both the influence of the fixed effect and the random effect.
Different estimation methods for non-linear mixed effects models have been extensively
discussed by other authors (e.g. [13, 14]). In this paper, due to the sparseness of the
simulated data, the Markov chain Monte Carlo stochastic approximation expectation-
maximization (SAEM) method [15, 16] is applied to the modeling of the simulated
time-concentration data according to the Master PK model. The true values of each
PK parameters as specified in Table 1 are used as initial values.
3 Results
For each scenario of the complete schedule and coarsened schedule designs, we report
1) % datasets ‘converged’. Due to the Monte Carlo nature of the SAEM method,
convergence testing is not formally done. Completed runs are counted as con-
vergence successes.
2) For each fixed and random effect: 6 fixed-effect terms, 6 random-effect terms,
and 2 residual error terms, among the B converged models,
– relative bias, RBias = 1
K
∑B
k=1(
βˆk−β
β
) ∗ 100,
– relative root mean squared error, RRMSE =
√
1
K
∑B
k=1(
βˆk−β
β
)2 ∗ 100, and
– coverage probability, CP=proportion of datasets with 95% confidence in-
tervals including the true value of the parameter β.
3) Shrinkage estimate for each random-effect terms, i.e. one minus the ratio of the
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standard deviation of the individual-level estimate and the estimated variability
for the population estimate.
3.1 Master popPK model
As an illustration, Figure 2 displays two expected population-level time-concentration
curves for individuals who are perfectly adherent to the 8-weekly infusion schedule,
one for the 10 mg/Kg dose and one for the 30 mg/Kg dose, based on the master
popPK model with E(bi) = 0, E(e1) = 0, and E(e2) = 0. The concentrations at
each time-point are simulated based on a body weight of 74.5 Kg and with the PK
parameter values given in Table 1.
In addition, a random set of the simulated individual-level concentration curves under
low study adherence are displayed in Figure 3. For example, individual #2 in the low
dose group (left panel) stayed in the study for follow up but discontinued infusions
after the first infusion, whereas individuals #9 and #26 in the high dose group (right
panel) dropped out of the study right after the first post-infusion visit.
3.2 Model fitting
3.2.1 Complete schedule marker sampling designs
Using the SAEM estimation method, almost all models using datasets under the com-
plete schedule designs converged to obtain final PK parameter estimates for m = 120
and m = 240, whereas a relative low convergence was observed for datasets with
m = 30 and m = 60 (Figure 4). This result suggests that a minimal sample size of
m = 60 is recommended for a stable PK model fitting under the described schedule.
This suggestion is further confirmed when the accuracy and precision of the fixed-effect
estimates are examined (Figures 5 &6, Supplementary Materials: Table 1). Reason-
able levels of bias and precision with significant improvements over the small sample
sizes are observed for m = 120. On the other hand, m = 240 provides relatively
marginal improvements compared to m = 120 except for βBW.CL, which characterizes
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the effect of each individual’s body weight on CL and requires data from a sufficient
number of independent subjects for an accurate and precise estimation.
Due to the unstable estimation for n = 30, we restrict the evaluation of the estimation
of random effects to larger sample sizes (Supplementary Materials: Figures S1 & S2).
In general, regardless of the sample size, the random effect of the PK parameter Q
(inter-compartmental clearance rate) is poorly estimated with high shrinkage (Supple-
mentary Materials: Figure S3). This poor estimation is due to the sparsity of data
closer to infusion, with only one 5-day post infusion time-point, and the low inter-
individual variability in Q. On the other hand, the estimation of CL and Vp seems
reasonable, with shrinkage generally below 20-30%. The proportional error term, σ21
is also reasonably estimated with RRMSE < 10% under all scenarios. The estimation
of the additive error term, σ22 is relatively poorer possibly due to the sparsity of data
around the assay limit of detection.
3.2.2 Coarsened schedule marker sampling designs
Figure 7 displays the distribution of the total number of observations (5 days after the
2nd infusion, 4 weeks and 8 weeks after each infusion) based on the 1000 simulated
datasets under each of the 12 coarsened schedule scenarios with m=240, along with
the complete schedule design with m=120. Because about half of the complete sched-
ule time-points are sampled in the coarsened schedules, the total expected number of
4-week and 8-week post infusion observations are the same across the 4 designs. This
feature allows a fair comparison across the designs. Meanwhile, the number of 5-day
post second infusion observations is doubled in the coarsened schedule designs, because
the 5-day post 2nd infusion time-point is the only time-point proximal to an infusion.
Hence, this time-point is always sampled from every individual under both the com-
plete and coarsened schedule designs. This consistency allows the assessment of the
impact of 5-day post infusion observations on the estimation of various PK parameters.
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Results showing the accuracy and precision of the fixed-effect estimates under each
coarsened schedule design with m = 240 are displayed in Figures 8, 9 and Supplemental
Materials (Table 2). The complete schedule design with m = 120 is included as a
reference for comparison purposes. In general, for the estimation of fixed effects, the
complete schedule design with half of the sample size provides more accurate but less
precise estimates, except that more accurate estimates are obtained for βVc and βBW.CL
under the ‘First half’ and ‘Mixed half’ coarsened schedule designs. This is likely
due to the fact that having more 5-day post infusion observations in the coarsened
schedule designs helps improve the estimation of βVc , which requires data proximal to
infusion for an accurate estimation, and having more independent individuals helps
improve the estimation of the covariate effect. On the other hand, the accuracy of
estimates under the coarsened schedule designs are more impacted by study adherence
due to the sparser time-points compared to the complete schedule design. Among
the 3 coarsened schedule designs, the ‘First half’ and ‘Mixed half’ designs have very
similar performance and are generally superior to the ‘Trough only’ design, especially
for the estimation of βVc . Similar patterns are observed in the estimation of random
effects (Supplemental Materials: Figures S4-S6). Poor estimation of the random effect
of inter-compartment clearance (Q) and additive residual error are observed for all
designs for reasons stated above.
4 Conclusions
PopPK analysis is known to be suitable for datasets consisting of a few data points
per individual over the course of product administration(s) from many individuals, in
order to estimate popPK parameters adjusting for variability among individuals. In
this paper, we investigated how the accuracy and precision of the estimated popula-
tion parameters (fixed effects) and variabilities among individuals (random effects) are
influenced by the number of individuals and by the number and type (i.e. time-point)
of observations per individual.
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In the context of the AMP study, where participants receive ten 8-weekly IV infusions
of VRC01, we considered complete schedule marker sampling designs where approxi-
mately 4-weekly observations from up to 22 time-points over the course of 80 weeks
are included in the popPK modeling, with 4 different levels of study adherence (per-
fect, high, medium, and low) and 4 different sample sizes (m= 30, 60, 120, and 240).
We found that a sample size of 120 or higher could render reasonably unbiased and
consistent estimates of most fixed and random effect terms. The central volume pa-
rameter Vc is the most challenging fixed effect parameter to estimate due to the lack
of concentration data proximal to infusion as specified in the AMP protocol.
We also considered coarsened schedule marker sampling designs with m = 240, where
the first half (‘First half’), alternate (‘Mixed half’), or ‘Trough only’ time-points are
included in the popPK modeling. These designs often provide less accurate but more
precise estimates of various popPK parameters than the complete schedule design with
m = 120. In terms of overall estimation performance as measured by RRMSE, the
‘First half’ and ‘Mixed half’ designs render similar performance, but are generally
superior to the ‘Trough only’ design and the complete schedule design. We note that
the ‘First half’ design is less subject to missing data, but provides limited data in the
assessment of the steady state and the effect of a higher number of repeated doses.
On the other hand, the ‘Mixed half’ design is more subject to missing data due to
infusion discontinuation and study drop out as the study progresses. Based on these
simulation results, we favor using the ‘Mixed half’ design for the AMP case-control
study, given that it provides the best overall accuracy and precision for various PK
parameter estimates in studies of high adherence like the current AMP study. In ad-
dition, the ‘Mixed half’ design allows the assessment of concentrations after any of
the ten infusions (as opposed to only the first five infusions in the ‘First half’ design);
these data may be helpful in the analysis and interpretation of other study endpoints
including long-term safety and anti-drug activity that may occur later in the study.
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If adherence declines in AMP, the advantages of the coarsened schedule designs will
diminish and the full schedule design may be considered.
In summary, this paper provides a simulation-based framework to evaluate sampling
designs of multiple-dose PK studies using a stochastic process for participants’ char-
acteristics (e.g. sex and body weight) and infusion/measurement time-points. It also
provides a simulator for studying statistical methods for assessing prevention efficacy
and correlates of prevention efficacy. This simulator not only accounts for participant
characteristics that influence PK processes, but also accounts for possible missed or
terminated product administrations, protocol-specific study visits and visit windows,
and potential drop out. Thus, this framework provides a realistic simulator of PK
data for future studies of repeatedly-administered drugs.
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Figure Legends
Figure 1: AMP study schema and marker sampling designs. Panel A: a
total of 2700 participants from the Americas and Switzerland trial and 1500 partici-
pants from the sub-Saharan Africa trial receive ten IV infusions (#1- #10) of VRC01
at 10 mg/Kg, 30 mg/Kg or placebo every 8-weekly at a 1:1:1 randomization ratio.
Arrows indicate pre- and post-infusion time-points included in the complete schedule
marker sampling design. Panel B: Orange circles indicate sampled time-points in each
coarsened schedule marker sampling design. Additional specimen collection times at
baseline (week 0) and after week 80 are not included in this figure because data at
these time-points mainly contribute to assay control and safety monitoring, not in the
PK modeling.
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Figure 2: Simulated time-concentration curves under the Master popPK
model following ten 8-weekly IV infusions of VRC01 in the 10 mg/Kg and
30 mg/Kg dose groups with perfect study adherence. Solid lines are the medi-
ans; shaded areas are the 2.5% and 97.5% percentiles of the concentrations over 1000
simulated datasets. A body weight of 74.5 Kg is used in the simulations.
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Figure 3: Simulated time-concentration curves under the Master popPK
model following ten 8-weekly IV infusions of VRC01 in the 10 mg/Kg and
30 mg/Kg dose groups with low study adherence. With low study adherence,
probability of an independently missed single infusion (p1), probability of an indepen-
dently missed post-infusion visit (p2), cumulative probability of permanent infusion
discontinuation (r1), and annual drop out rate (r2) are assumed to be 15%, 20%, 20%,
and 20%, respectively.
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Figure 4: Percent of models converged under the complete schedule de-
signs with different levels of study adherence and sample sizes (m = 30, 60,
120, and 240.) The four study adherence patterns in terms of (p1, p2, r1, r2) are:
Perfect = (0%, 0%, 0%, 0%), High = (5%, 10%, 10%, 10%), Medium = (10%, 15%,
15%, 15%), and Low = (15%, 20%, 20%, 20%), where p1 indicates the probability of
an independently missed single infusion, p2 the probability of an independently missed
post-infusion visit, r1 the cumulative probability of permanent infusion discontinua-
tion, and r2 the annual drop out rate.
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Figure 5: Relative bias of each fixed-effect PK parameter estimate un-
der complete schedule designs with different sample sizes (m = 30, 60, 120,
and 240). βCL, βVc , βQ, and βVp indicate the fixed effect for CL, Vc, Q, and Vp,
respectively. βBW.CL and βBW.Vc indicate the fixed effect of body weight influence on
CL and Vc, respectively.
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Figure 6: Relative root mean squared errors of each fixed-effect PK pa-
rameter estimate under complete schedule designs with different sample
sizes (m = 30, 60, 120, and 240). βCL, βVc , βQ, and βVp indicate the fixed effect
for CL, Vc, Q, and Vp, respectively. βBW.CL and βBW.Vc indicate the fixed effect of body
weight influence on CL and Vc, respectively.
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Figure 7: Distributions of the total numbers of 5-day post 2nd infusion,
4-week post infusion, and 8-week post infusion observations under the com-
plete schedule design with m = 120 and 3 coarsened schedule designs with
m = 240. The ‘First half’ design samples the first 11 time-points (excluding time 0)
out of the total 22 complete schedule time-points. The ‘Mixed half’ design samples
time-points after every other infusion. The ‘Trough only’ design samples only trough
time-points. All 3 coarsened schedule designs always include the 5-day post 2nd infu-
sion time-point.
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Figure 8: Relative bias of each fixed-effect PK parameter estimate un-
der coarsened schedule designs with m = 240 compared to the complete
schedule design with m = 120. βCL, βVc , βQ, and βVp indicate the fixed effect for
CL, Vc, Q, and Vp, respectively. βBW.CL and βBW.Vc indicate the fixed effect of body
weight influence on CL and Vc, respectively. The ‘First half’ design samples the first
11 time-points (excluding time 0) out of the total 22 complete schedule time-points.
The ‘Mixed half’ design samples time-points after every other infusion. The ‘Trough
only’ design samples only trough time-points. All 3 coarsened schedule designs always
include the 5-day post 2nd infusion time-point.
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Figure 9: Relative root mean squared errors of each fixed-effect PK
parameter estimate under coarsened schedule designs with m = 240 com-
pared to the complete schedule design with m = 120. βCL, βVc , βQ, and
βVp indicate the fixed effect for CL, Vc, Q, and Vp, respectively. βBW.CL and βBW.Vc
indicate the fixed effect of body weight influence on CL and Vc, respectively. The
‘First half’ design samples the first 11 time-points (excluding time 0) out of the to-
tal 22 complete schedule time-points. The ‘Mixed half’ design samples time-points
after every other infusion. The ‘Trough only’ design samples only trough time-points.
All 3 coarsened schedule designs always include the 5-day post 2nd infusion time-point.
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Supplemental materials
Table 1: Fixed effects PK parameter estimation accuracy and precision un-
der complete schedule design scenarios. βCL, βVc , βQ, and βVp indicate the fixed
effect for CL, Vc, Q, and Vp, respectively. βBW.CL and βBW.Vc indicate the fixed effect
of body weight influence on CL and Vc, respectively. The four study adherence pat-
terns in terms of (p1, p2, r1, r2) are: Perfect = (0%, 0%, 0%, 0%), High = (5%, 10%,
10%, 10%), Medium = (10%, 15%, 15%, 15%), and Low = (15%, 20%, 20%, 20%),
where p1 = probability of an independently missed single infusion, p2 = probability of
an independently missed post-infusion visit, r1 = cumulative probability of permanent
infusion discontinuation, and r2 = annual drop out rate. RBias = average relative bias,
RRMSE = average relative root mean squared error, and CP = coverage probability.
Parameter Sample size Study adherence RBias (%) RRMSE CP (%)
βCL
30
Low 11.9 26.07 95.12
Medium 7.91 24.27 97.54
High 5.7 16.84 97.98
Perfect 4.6 18.78 98.14
60
Low 0.43 10.87 98.85
Medium -0.56 9.7 99.29
High -0.45 9.61 98.79
Perfect -1.9 8.93 99.4
120
Low 0.88 6.99 98
Medium 0.11 6.37 99
High 0.18 5.77 98.9
Perfect -0.4 5.17 99.4
240
Low 1.36 4.46 98
Medium 0.69 4.07 98.6
High 0.4 3.99 99.1
Perfect -1.23 3.77 99.5
βVc
30
Low 35.46 90.46 94.7
Medium 17.68 76.53 95.47
High 12.83 68.4 96.79
Perfect 4.05 62.86 96.83
60
Low -1.09 47.74 97.49
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Table 1: (continued)
Parameter Sample size Study adherence Relative bias (%) RRMSE CP (%)
Medium -6.91 42.71 97.35
High -5.62 42.12 97.37
Perfect -9.96 38.26 97.7
120
Low 3.03 35.48 98.2
Medium -1.39 31.61 99.1
High -2.83 28.33 98.6
Perfect -5.51 25.32 99.2
240
Low 3.39 23.28 99.1
Medium -1.14 20.82 99.4
High -2.3 20.38 98.9
Perfect -9.65 19.31 98.4
βQ
30
Low 9.63 53.81 97.77
Medium 7.13 50.32 98.96
High 6.75 49.24 99.52
Perfect 2.93 37.07 99.45
60
Low -0.06 31.05 99.69
Medium -1.15 28.55 99.69
High -0.43 27.7 100
Perfect -3.51 24.35 99.5
120
Low 3.65 20.78 99.5
Medium 2.76 20.01 99.5
High 2.92 17.74 99.5
Perfect 1.37 15.5 99.8
240
Low 5.53 14.18 99.4
Medium 4.13 13.58 99
High 3.62 12.69 98.9
Perfect -0.83 10.86 99.4
βVp
30
Low 3.86 33.95 99.58
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Table 1: (continued)
Parameter Sample size Study adherence Relative bias (%) RRMSE CP (%)
Medium 2.19 34.38 99.35
High 0.6 22.19 99.64
Perfect 1.08 25.84 99.78
60
Low -1.44 13.76 99.79
Medium -1.57 11.94 99.49
High -1.44 11.95 99.9
Perfect -2.14 10.7 99.9
120
Low 0.64 7.95 99.3
Medium 0.43 7.27 99
High 0.81 6.46 98.8
Perfect 0.27 5.92 99
240
Low 1.92 4.77 97.9
Medium 1.64 4.49 98.2
High 1.26 4.45 98.3
Perfect 0.13 3.95 99
βBW.CL
30
Low -12.15 68.68 97.21
Medium -17.1 67.58 96.89
High -17.78 63.76 98.1
Perfect -13.88 60.21 97.49
60
Low -14.27 50.84 89.44
Medium -17.63 50.81 86.85
High -14.88 46.7 86.94
Perfect -14.61 43.61 87.88
120
Low -9.1 35.43 86.17
Medium -7.43 32.67 87.2
High -4.72 28.63 90.4
Perfect -5.11 25.98 92.2
240
Low -2.98 20.97 92.2
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Table 1: (continued)
Parameter Sample size Study adherence Relative bias (%) RRMSE CP (%)
Medium -3.4 21.33 90.4
High -1.38 16.18 95.7
Perfect -2.24 13.88 96.2
βBW.Vc
30
Low 83.58 175.16 96.79
Medium 99.46 405.73 97.67
High 70.13 195.68 97.62
Perfect 69.14 152.71 98.14
60
Low 28.14 97.78 97.8
Medium 22.03 89.87 98.27
High 20.75 90.84 98.18
Perfect 12.48 80.15 97.7
120
Low 0.83 70.7 98
Medium -0.23 66.91 97.3
High 5.68 64.54 96.5
Perfect 1.52 58.06 97.4
240
Low -1.85 51.33 96.7
Medium 0.5 50.1 96.7
High 2.36 46.26 95.5
Perfect 1.55 40.76 95.6
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Table 2: Fixed effects PK parameter estimation accuracy and precision un-
der coarsened schedule design scenarios with n=240. βCL, βVc , βQ, and βVp
indicate the fixed effect for CL, Vc, Q, and Vp, respectively. βBW.CL and βBW.Vc indicate
the fixed effect of body weight influence on CL and Vc, respectively. The four study
adherence patterns in terms of (p1, p2, r1, r2) are: Perfect = (0%, 0%, 0%, 0%), High
= (5%, 10%, 10%, 10%), Medium = (10%, 15%, 15%, 15%), and Low = (15%, 20%,
20%, 20%), where p1 = probability of an independently missed single infusion, p2 =
probability of an independently missed post-infusion visit, r1 = cumulative probabil-
ity of permanent infusion discontinuation, and r2 = annual drop out rate. RBias =
average relative bias, RRMSE = average relative root mean squared error, and CP =
coverage probability.
Parameter Sampling design Study adherence RBias (%) RRMSE CP (%)
βCL
m=240 First half
Low 2.4 5.24 95.5
Medium 1.83 4.78 96.9
High 1.6 4.76 96.8
Perfect 0.35 4.05 98.3
m=240 Mixed half
Low 2.23 5.49 96.5
Medium 1.8 5.13 96.3
High 1.85 4.54 97.3
Perfect 0.43 3.93 98.9
m=240 Trough only
Low 4.25 6.74 92.4
Medium 3.28 6.02 93.7
High 2.75 5.34 95.2
Perfect 1.8 4.56 97.2
m=120 Full
Low 0.88 6.99 98
Medium 0.11 6.37 99
High 0.18 5.77 98.9
Perfect -0.4 5.17 99.4
βVc
m=240 First half
Low 11.34 29.68 98.6
Medium 7.35 25.86 98.7
High 6.4 25.73 98.2
Perfect 0.72 20.42 98.8
m=240 Mixed half
Low 11.51 31.2 98.6
Medium 7.51 27.46 98.5
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Table 2: (continued)
Parameter Sampling design Study adherence Relative bias (%) RRMSE CP (%)
High 7.21 24.45 99.1
Perfect 0.71 19.47 98.9
m=240 Trough only
Low 21.97 37.87 97.4
Medium 16.57 33.08 97.8
High 13.65 29.21 98.4
Perfect 10.85 25.2 99
m=120 Full
Low 3.03 35.48 98.2
Medium -1.39 31.61 99.1
High -2.83 28.33 98.6
Perfect -5.51 25.32 99.2
βQ
m=240 First half
Low 7.71 15.94 98.8
Medium 6.69 15.05 98.5
High 6.32 14.64 97
Perfect 3.21 12.31 97.9
m=240 Mixed half
Low 6.79 15.98 99.4
Medium 6.47 15.99 98
High 7.05 14.4 98.1
Perfect 3.4 11.71 98.4
m=240 Trough only
Low -1.04 13.55 98.3
Medium 0.99 13.71 98.3
High 3.52 13.98 99
Perfect 4.12 13.12 98.6
m=120 Full
Low 3.65 20.78 99.5
Medium 2.76 20.01 99.5
High 2.92 17.74 99.5
Perfect 1.37 15.5 99.8
βVp
m=240 First half
Low 1.66 4.75 97.5
Medium 1.55 4.54 97.4
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Table 2: (continued)
Parameter Sampling design Study adherence Relative bias (%) RRMSE CP (%)
High 1.17 4.56 97.7
Perfect 0.68 4.03 98
m=240 Mixed half
Low 1.1 4.86 98.4
Medium 1.24 4.71 97.4
High 1.47 4.3 97.8
Perfect 0.78 4.13 98.2
m=240 Trough only
Low 1.37 5.01 98
Medium 1.21 4.69 97.9
High 1.1 4.48 98.5
Perfect 0.77 3.94 98.8
m=120 Full
Low 0.64 7.95 99.3
Medium 0.43 7.27 99
High 0.81 6.46 98.8
Perfect 0.27 5.92 99
βBW.CL
m=240 First half
Low -2.11 23.94 90.3
Medium -1.6 22.91 89.7
High -0.68 20.43 91.4
Perfect -1.14 18.12 93
m=240 Mixed half
Low -4.17 27 87.7
Medium -2.49 24.61 89.6
High -1.09 21.12 92.2
Perfect -0.63 16.9 94.3
m=240 Trough only
Low -3.73 33.35 85.6
Medium -5.87 33.07 86
High -3.31 30.86 88.3
Perfect -2.91 25.49 89.8
m=120 Full
Low -9.1 35.43 86.17
Medium -7.43 32.67 87.2
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Table 2: (continued)
Parameter Sampling design Study adherence Relative bias (%) RRMSE CP (%)
High -4.72 28.63 90.4
Perfect -5.11 25.98 92.2
βBW.Vc
m=240 First
Low -2 54.42 96.7
Medium -1.1 54.68 96.2
High 0.84 50.76 95.6
Perfect 2.45 45.73 95.2
m=240 Mixed half
Low -5.88 58.98 96.7
Medium -2.13 55.02 95.8
High -1.15 52.32 95.7
Perfect 2.98 45.23 94.3
m=240 Trough only
Low 2.14 68.17 94.8
Medium -2.06 63.8 95.1
High 2.49 64.63 94.4
Perfect 1.45 56.91 96.3
m=120 Full
Low 0.83 70.7 98
Medium -0.23 66.91 97.3
High 5.68 64.54 96.5
Perfect 1.52 58.06 97.4
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Figure S1: Relative bias of each random-effect PK parameter estimate
under complete schedule designs with different sample sizes (m = 60, 120,
and 240). var(bCL), var(bQ), and var(bVp) are the variances of the random effects
for CL, Q, and Vp, respectively. cov(bCL, bQ), cov(bCL, bVp), and cov(bCL, bVc) are the
covariances between the respective random effects. σ21 and σ
2
2 are the proportional and
additive error variances, respectively.
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Figure S2: Relative root mean squared errors of each random-effect PK
parameter estimate under complete schedule designs with different sample
sizes (m = 60, 120, and 240). var(bCL), var(bQ), and var(bVp) are the variances
of the random effects for CL, Q, and Vp, respectively. cov(bCL, bQ), cov(bCL, bVp), and
cov(bCL, bVc) are the covariances between the respective random effects. σ
2
1 and σ
2
2 are
the proportional and additive error variances, respectively.
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Figure S3: Shrinkage estimates under complete schedule design scenar-
ios. bCL, bQ, and bVp are the random effects for CL, Q, and Vp, respectively.
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Figure S4: Relative bias of each random-effect PK parameter estimate
under coarsened schedule designs with m = 240 compared to the complete
schedule design with m = 120. var(bCL), var(bQ), and var(bVp) are the variances
of the random effects for CL, Q, and Vp, respectively. cov(bCL, bQ), cov(bCL, bVp), and
cov(bCL, bVc) are the covariances between the respective random effects. σ
2
1 and σ
2
2 are
the proportional and additive error variances, respectively.
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Figure S5: Relative root mean squared errors of each random-effect
PK parameter estimate under coarsened schedule designs with m = 240
compared to the complete schedule design with m = 120. var(bCL), var(bQ),
and var(bVp) are the variances of the random effects for CL, Q, and Vp, respectively.
cov(bCL, bQ), cov(bCL, bVp), and cov(bCL, bVc) are the covariances between the respective
random effects. σ21 and σ
2
2 are the proportional and additive error variances, respec-
tively.
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Figure S6: Shrinkage estimates under coarsened schedule designs with
m = 240 compared to the complete schedule design with m = 120. The
‘First half’ design samples the first 11 time-points (excluding time 0) out of the total
22 complete schedule time-points. The ‘Mixed half’ design samples time-points after
every other infusion. The ‘Trough only’ design samples only trough time-points. All 3
coarsened schedule designs always include the 5-day post 2nd infusion time-point. bCL,
bQ, and bVp are the random effects for CL, Q, and Vp, respectively.
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HVTN 704/HPTN 085 
Study Specific Procedures 
Visit Scheduling and Coding  
February 26, 2016 
To ensure completeness and accuracy of data submitted to the statistical and data 
management center (SDMC), proper visit scheduling and coding is essential. This 
section describes the processes involved in visit scheduling and coding of study 
visits on case report forms (CRFs).    
1. Visit Schedules 
There will be four separate visit schedule tracks in the HVTN 704/HPTN 085 study:  
 Schedule 1: HIV-uninfected participants 
 Schedule 2: HIV-1-infected participants 
 Schedule 3: Participants discovered to have been HIV-1-infected at 
enrollment or who become HIV-2-infected  
 Schedule 4: Participants who discontinue infusions for reasons other than 
HIV infection 
Infusion visits will only occur within Schedule 1.  
2. Study Visit Timing 
All visits should take place within the “target visit windows”. Infusion visits and some 
Schedule 2, 3, and 4 visits have an expanded “allowable visit window” that may be 
utilized only if the visit cannot be scheduled within the target visit window. The visit 
windows are used by DataFax to query for an “overdue” visit and in the Retention 
Reports to determine whether a visit has been conducted “early” or “late.”   
2.1. Visit Windows 
The visit windows for each HVTN 704/HPTN 085 schedule are listed in Tables 1-4. 
Sites should verify visit windows prior to scheduling participant visits and again prior 
to conducting the visit.  This should be done by using the HVTN 704/HPTN 085 Visit 
Calculator spreadsheet, posted on the HVTN 704/HPTN 085 home page: 
https://members.hvtn.org/protocols/hvtn704-hptn085/SitePages/Home.aspx or, if 
unavailable, then by using another reliable mechanism such as a Scheduling Wheel-
Chart.  As visit windows for HIV-uninfected participants are dynamic and based on 
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the prior infusion date (see Section 2.1.1 below), the most current participant visit 
schedule should be used (not a static printout). 
If more than one infusion visit for a single participant occurs within one 49 day period 
this is considered a protocol event. Submit a Protocol Event and Critical Event form 
(PECEF) to the Clinical Trials Manager (CTM)/Clinical Research Manager (CRM) 
(vtn704.ptn085.ctm.crm@hvtn.org) and complete the Protocol Event Log CRF (refer 
to the SSP section on Protocol Events and Critical Events for more information). 
2.1.1. Visit Windows for Participants in the HIV-Uninfected Schedule (Schedule 1) 
An idealized visit schedule is depicted in Appendix J of the HVTN 704/HPTN 085 
protocol Version 1.0; however, visit windows are dynamic and must always be 
determined according to the date the prior infusion visit occurred (as such, it is 
expected that Appendix J may not be an appropriate guide for visit windows for most 
of a participant’s study visits).   
Infusion Visits 
All infusion visits must be at least 49 days apart. Target days, target windows, 
and allowable windows of an infusion are based upon the date of the prior infusion 
visit. If an infusion visit is missed, the subsequent infusion should be scheduled 
within a visit window that is based on the target day of the prior (missed) infusion.  
Sites should attempt to schedule infusion visits within the target visit window but 
have the option of utilizing the upper allowable window if needed. There is no “lower 
allowable window” for an infusion visit: the target window for any infusion visit 
encompasses the earliest possible dates at which the infusion may be conducted; 
the “upper allowable window” for any infusion visit encompasses the latest possible 
dates at which the infusion may be conducted. 
Post-Infusion Visits 
All post-infusion visits are scheduled according to the date of the prior infusion visit.  
When an infusion visit is missed, the 5-day post-infusion visit (if applicable) and 4-
week post-infusion visit are also considered missed (see Section 2.4 below).  If visit 
21 (infusion #10) is missed, visits 23-26 should be scheduled based on the date of 
the target day of the missed visit 21. Subsequent infusion visit windows are not 
impacted if a post-infusion visit is missed.   
Scenarios 
Refer to HVTN 704/HPTN 085 Visit Scheduling and Coding SSP Appendix, Visit 
Window Scenarios and Schematics for an illustration of how the dynamic visit 
windows can be modified for different scenarios during the trial. 
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Table 1: Visit Windows for HIV-uninfected Participants (Schedule 1) 
 
Visit Number(s) Visit Type 
Lower 
Target/ 
Allowable 
Window 
Target Day 
Upper 
Target 
Window 
Upper 
Allowable 
Window 
01.0 Screening -56¹  - - 
02.0 Enrollment/Infusion #1¹ - 0 - - 
04.0 
07.0 
09.0 
11.0 
13.0 
15.0 
17.0 
19.0 
21.0 
Infusions #2-10² -7 
prior infusion 
visit date + 56 
days 
+7 +48 
05.0 5-day post-infusion #2³ -2 
Visit 4 date + 
5 days 
+2 - 
03.0 
06.0 
08.0 
10.0 
12.0 
14.0 
16.0 
18.0 
20.0 
22.0 
4-week post-infusion #2-10³ 
 
-7 
prior infusion 
visit date + 28 
days 
+7 - 
23.0 8-week post-infusion #10³ -7 
Visit 21 date + 
56 days 
+7 - 
24.0 12-week post- infusion #10³ -7 
Visit 21 date + 
84 days 
+7 - 
25.0 16-week post –infusion #10³ -7 
Visit 21 date + 
112 days 
+7 - 
26.0 
Final Visit (20-week post-
infusion #10)³ 
-7 
Visit 21 date + 
140 days 
+7 - 
 
¹ Screening HIV testing must be performed within 30 days of Enrollment/Infusion #1. 
² Infusions must occur at least 49 days apart and are scheduled according to the date of the prior infusion visit. 
³ Post-infusion visits are scheduled according to the date of the prior infusion visit. 
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2.1.2. Visit Windows for Participants in the HIV-infected Schedules (Schedule 2 and 
Schedule 3) 
All target days are relative to the date of HIV infection diagnosis. The date of HIV 
diagnosis is defined as the specimen collection date of the first sample that leads to 
a positive result by the HIV diagnostic algorithm. Refer to the HIV Testing and 
Counseling SSP section for further guidance on the HIV testing algorithm, and the 
Participant Follow-up SSP section for further guidance on transitioning to Schedule 2 
or 3.    
Table 2: Visit Windows for HIV-1-infected Participants (Schedule 2) 
Visit 
Number 
Visit Type 
Lower 
Allowable 
Window 
Lower 
Target 
Window 
Target Day 
(days after 
diagnosis) 
Upper 
Target 
Window 
Upper 
Allowable 
Window 
#.x 
(Interim 
visit) 
Confirmatory draw 
(HIV diagnostics) 
(2 weeks after 
diagnosis) 
 
- -12 14 +7 - 
31.0* 4-weeks post 
diagnosis* 
- -4* 28* +4* - 
32.0 6-weeks post 
diagnosis 
- -4 42 +4 - 
33.0 8-weeks post 
diagnosis 
- -4 56 +4 - 
34.0 12-weeks post 
diagnosis 
-14 -7 84 +7 +14 
35.0 
24-weeks post 
diagnosis 
(Final Visit) 
-28 -14 168 +14 +28 
Note: All visits are relative to the HIV infection diagnosis date (not shown on this table). 
* Note that confirmatory HIV test results may or may not be available by the opening of the 4-week post diagnosis visit 
window. Sites should verify availability of confirmatory HIV test results with the HVTN Laboratory Program if 
scheduling this visit prior to the target day. Questions should be directed to: VTN704.PTN085.askHIV@hvtn.org. 
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Table 3: Visit Windows for Participants discovered to have been HIV-1-infected at Enrollment or 
who become HIV-2 infected (Schedule 3) 
Visit 
Number 
Visit Type 
Lower 
Allowable 
Window 
Lower 
Target 
Window 
Target 
Day 
(days after 
diagnosis) 
Upper 
Target 
Window 
Upper 
Allowable 
Window 
#.x 
(Interim 
visit) 
Confirmatory draw 
(HIV diagnostics) 
(2 weeks after 
diagnosis) 
 
- -7 14 +7 - 
47.0** 4-weeks post 
diagnosis** 
- -4** 28** +14 - 
48.0 
24-weeks post 
diagnosis 
(Final Visit) 
-28 -14 168 +14 +28 
Note: All visits are relative to the HIV infection diagnosis date (not shown on this table). 
**Sites should verify availability of confirmatory HIV test results with the HVTN Laboratory Program if scheduling this 
visit prior to the target day. Questions should be directed to: VTN704.PTN085.askHIV@hvtn.org. 
 
2.1.3. Visit Windows for Participants who Discontinue Infusions for Reasons Other Than 
HIV Infection (Schedule 4) 
All target days are relative to the date of Enrollment. Once a participant has been 
administratively transitioned to Schedule 4 (see Participant Follow-up SSP section 
for more information), the participant should be scheduled for the next consecutive 
study visit within Schedule 4 based on the date (i.e. study day) of the previous visit in 
Schedule 1. For example, if a participant’s infusions are discontinued at the 
Enrollment visit (Day 0), their next study visit in Schedule 4 should be visit 71 (8 
week post enrollment visit), scheduled around target day 56. If a participant’s 
infusions are discontinued on day 190, their next study visit in Schedule 4 should be 
visit 74 (44 weeks post enrollment), scheduled around target day 308. This is 
because day 190 (date of discontinuation) is within the visit window for visit 73 (32 
weeks post enrollment), so the next consecutive study visit is visit 74. Sites are 
encouraged to use the AMP Visit Calculator Excel spreadsheet tool to determine the 
point of entry into Schedule 4.  
If a participant is transitioned to Schedule 4 due to a clinical or safety concern, 
additional interim visits (see Section 2.3 below), in addition to the visits reflected in 
Schedule 4, may be appropriate. The clinical safety staff (Clinical Safety Specialist 
[CSS]/Regional Medical Liaison [RML]) should be contacted at 
VTN704.PTN085.CSS.RML@hvtn.org if a participant is transitioned to Schedule 4 
due to a clinical or safety concern. They will work with the HVTN 704/HPTN 085 
Protocol Safety Review Team (PSRT) and the Clinical Research Site (CRS) to 
determine the most appropriate follow-up schedule.  
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Table 4: Visit Windows for Participants Who Discontinue Infusions for Reasons Other Than HIV 
Infection (Schedule 4) 
Visit 
Number 
Visit Type 
Lower 
Allowable 
Window 
Lower 
Target 
Window 
Target 
Day 
(days after 
enrollment) 
Upper 
Target 
Window 
Upper 
Allowable 
Window 
71.0 8 weeks post enrollment -55 -14 56 +14 +42 
72.0 20 weeks post 
enrollment 
-41 -14 140 +14 +42 
73.0 32 weeks post 
enrollment 
-41 -14 224 +14 +42 
74.0 44 weeks post 
enrollment 
-41 -14 308 +14 +42 
75.0 56 weeks post 
enrollment 
-41 -14 392 +14 +42 
76.0 68 weeks post 
enrollment 
-41 -14 476 +14 +42 
77.0 80 weeks post 
enrollment 
-41 -14 560 +14 +42 
78.0 92 weeks post 
enrollment 
-41 -14 644 +14 +42 
Note: All visits are relative to enrollment date 
 
2.2. Split Visits 
When a participant is not able to complete all required visit procedures on the same 
day, the participant may return and complete the remaining procedures on another 
day, as long as the procedures are completed within the allowable window for that 
visit.  
CRS staff must make every effort to complete the infusion visit in one calendar day.  
To avoid issues from split infusion visits, such as repeat blood draws or blood draw 
volumes exceeding the 56-day blood volume maximum, it is recommended that, prior 
to collecting blood samples, sites perform all procedures and evaluations necessary 
to confirm that the participant can proceed with infusion. This includes conducting the 
abbreviated physical exam and pregnancy testing (if required) and soliciting adverse 
events (AEs) and other possible contraindications to infusion. 
However, when a split visit must occur at an infusion visit (e.g., due to intercurrent 
illness or other contraindication to receipt of study product) follow the guidance 
below: 
 Pregnancy test, if required, must be repeated on the day of infusion, and the 
result confirmed negative prior to infusion, (see Specimen Collection SSP, 
Pregnancy Testing Section 5).  
 Blood specimens (immunogenicity, safety labs, and HIV testing) must be 
collected within 3 days prior to infusion.  If blood has already been collected 
and infusion must be delayed, attempt to bring participant back for infusion 
within 3 days to avoid re-draw.  If participant does not return within 3 days, 
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blood will need to be redrawn according to the Specimen Collection SSP 
sections on Specimen Collection Priorities and Instructions for Short Draws, 
taking into consideration the 56-day blood draw volume limitation. 
 Physical exams must be performed on the day of infusion.  
When a split visit occurs, all CRFs completed for the visit are assigned the same visit 
code, even though some forms or procedures will have different visit dates. For 
Schedule 1 visits, the subsequent post-infusion visit window and subsequent infusion 
visit window will be based on the date the infusion was performed.  
2.3. Interim Visits 
In addition to the scheduled protocol-required visits, interim visits may occur after 
enrollment in the trial. A clinic visit is considered an interim visit when study data are 
collected on CRFs during a clinic visit that occurs for  reasons other than to complete 
regularly scheduled (required) study visit procedures, or, when allowed (see Section 
2.4 below), to complete procedures for a regular study visit that could not be 
conducted during the visit window.  
Interim visits may be performed at any time during the study for reasons that are 
administrative (e.g., a participant has study-related questions for the staff), lab-
related (e.g., a participant needs a lab test repeated for confirmation), or clinical 
(e.g., a participant needs additional clinical follow-up for an AE). Phone or e-mail 
contact with a participant can also be considered an interim visit if study data are 
collected on a CRF. 
If no CRFs are required (e.g., the participant comes to the clinic to obtain more 
condoms), this is not considered an interim visit and you should not complete the 
Interim Visit CRF; however, the contact should be documented by a chart note. 
2.3.1. Interim Visit Codes 
Interim visit codes are assigned using the following guidelines: 
 In the boxes to the left of the decimal point, record the two-digit visit code for 
the most recent scheduled visit (even if a Missed Visit CRF was completed 
for that visit). 
 Use the guide below to complete the box to the right of the decimal point: 
1 = the first interim visit after the most recent scheduled visit, 
2 = the second interim visit after the most recent scheduled visit, 
3 = the third interim visit after the most recent scheduled visit, and so on. 
For example, the first interim visit after the Enrollment Visit would be recorded as 
follows: 
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The second interim visit after the participant’s third scheduled study visit would be 
recorded as follows: 
 
2.4. Missed Visits 
A visit not performed within the specified visit windows (see above Section 2.1) is 
considered a missed visit and a Missed Visit CRF must be submitted for that visit. 
The Missed Visit CRF should only be completed and submitted for a visit once the 
visit window for that visit has closed. Below is additional guidance for specific types 
of missed visits. 
Infusion Visits 
If an infusion visit’s allowable window closes and the infusion has not been 
completed, the infusion visit is considered missed.  If an infusion visit is missed, the 
associated post-infusion visit is automatically considered missed as well, and the 
subsequent infusion visit window should be determined based on the target day of 
the prior (missed) infusion. CRS staff should attempt to bring the participant in to 
complete the next infusion visit. 
Post-Infusion Visits  
If the missed visit is a post-infusion visit for an infusion visit that was completed, a 
Missed Visit CRF should be submitted to DataFax. If possible, the CRS staff should 
attempt to bring the participant in for an interim visit. At the interim visit, all post-
infusion visit protocol-required procedures should be conducted. 
If the missed visit is a post-infusion visit due to a missed infusion visit, a Missed 
Visit CRF does NOT need to be submitted for the missed post-infusion visit (a 
missed infusion visit automatically turns off the expectation in DataFax for the post-
infusion visit). CRS staff should attempt to bring the participant in to complete the 
next infusion visit as soon as possible. 
Schedule 2 and 3 Visits 
If the missed visit is a Schedule 2 or Schedule 3 visit, CRS staff should attempt to 
bring the participant in for an interim visit. At the interim visit, all protocol-required 
procedures for the missed visit should be conducted.  
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Schedule 4 Visits 
As Schedule 4 visit windows are adjacent, if a Schedule 4 visit is missed, the CRS 
staff should attempt to bring the participant in for the next Schedule 4 visit as soon as 
possible. 
3. Termination and Reactivation 
Participants are terminated from study participation when they have completed the 
final study visit, died, refused further participation in the study, relocated, CRS staff 
can no longer contact the participant (lost-to-follow-up), or the investigator has 
decided they can or should no longer participate. Participants who have been 
terminated from the study due to lost-to-follow-up, refusal, or relocation and then 
return to the study site before the close of the visit window of their exit visit may be 
allowed to rejoin the study, and should be encouraged to do so. Participants are 
reactivated by writing “unterminate” or “delete” on the previously submitted 
Termination CRF and retransmitting to DataFax. Please note that a Missed Visit CRF 
must be completed for each missed visit during the period the participant was not in 
contact with the site.  Refer to Last Scheduled Study Visit section of the SSP for 
more information.  
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Appendix: 
HVTN 704/HPTN 085 Visit Scheduling and 
Coding SSP
Visit Window Scenarios and Schematics
A. Ppt completes 1st infusion
Visit window est. from inf. #1 date
Visit window established from infusion #1 
dateInf 1
Week 0
4-wk post
Inf 2
B. Ppt completes 4-week post after 1st infusion
Visit window est. from inf. #1 date
Inf 1
Week 0
4-wk post
week 4
Inf 2
C. Ppt completes 2nd infusion
D. Ppt completes 4-week post after 2nd infusion
E. Ppt completes 3rd infusion
Scenario 1:
Participant completes visits on target
dates in middle of target windows
Scale (study weeks):
0 4 8 12
Legend:
Infusion visit completed
Target infusion window
Allowable  infusion window
4-week post-infusion visit completed
4-week post –infusion visit window
5-day post-infusion visit completed
5-day post-infusion visit window
Inf 1
Week 0
4-wk post
week 4
Inf 2
week 8
Visit window est. from inf. #2 date
Inf 3
4-wk post
Visit windows est. from inf. #2 date
5-d post
4-wk post
week 4
Inf 2
week 8
Visit window est. from inf. #2 date
Inf 3
4-wk post
week 12
(week 8 + 4)
Inf 1
Week 0
5-d post
4-wk post
week 4
Inf 2
week 8
Inf 3
week 16
(week 8 + 8)
4-wk post
week 12
Inf 1
Week 0
Visit window est. from inf. #3 date
Inf 4
4-wk post
Visit window est. from inf. #3 date
5-d post
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Scenario 1: 
Participant completes visits on target 
dates in middle of target windows
A. Participant completes first infusion on day 0 of week 0. 
Two visit windows are created based on the date of the 
infusion:  a 4-week post-infusion visit window centered on 
week 4 and an infusion visit window that allows the next 
infusion between 49 and 105 days (7 weeks – 15 weeks) 
later. Note that the target window is between day 49 and 
day 65 (first two weeks of window), but the database will 
allow an infusion visit through day 105.
B. Participant completes the 4-week post-infusion visit after 
the first infusion.  The visit window for the 4-week post 
visit closes. The visit window for the second infusion is 
unaffected.
C. Participant completes the 2nd infusion on the target date 
(middle of window).  The 2nd infusion window closes when 
the infusion is received. Being the second infusion, the 
completion of this infusion creates three new visit 
windows: a 5-day post infusion visit window, a 4-week 
post-infusion visit window centered on week 12, and the 
third infusion visit window 7-15 weeks after infusion #2.
D. Participant completes 5-day post and 4-week post visits 
after 2nd infusion.  The visit windows for these visits close; 
the window for the 3rd infusion visit is unaffected.
E. Participant completes the third infusion, closing the 
infusion window. The 4-week post visit window and the 
window for the next infusion are created as described 
above.
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A. Ppt completes 1st infusion
Visit window est. from inf. #1 date
Visit window established from infusion #1 
dateInf 1
Week 0
4-wk post
Inf 2
B. Ppt completes 4-week post after 1st infusion
Visit window est. from inf. #1 date
Inf 1
Week 0
4-wk post
week 5
Inf 2
C. Ppt completes 2nd infusion
D. Ppt completes 4-week post after 2nd infusion
E. Ppt completes 3rd infusion
Scenario 2:
Participant completes visits on dates  
toward end of target windows
Inf 1
Week 0
4-wk post
week 5
Inf 2
week 9
Visit window est. from inf. #2 date
Inf 3
4-wk post
Visit windows est. from inf. #2 date
5-d post
4-wk post
week 5
Inf 2
week 9
Visit window est. from inf. #2 date
Inf 3
4-wk post
week 14
(week 9 +5)
Inf 1
Week 0
5-d post
4-wk post
week 5
Inf 2
week 9
Inf 3
week 18
(week 9 + 9)
4-wk post
week 14
Inf 1
Week 0
Visit window est. from inf. #3 date
Inf 4
4-wk post
Visit window est. from inf. #3 date
5-d post
Scale (study weeks):
0 4 8 12
Legend:
Infusion visit completed
Target infusion window
Allowable  infusion window
4-week post-infusion visit completed
4-week post –infusion visit window
5-day post-infusion visit completed
5-day post-infusion visit window
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Scenario 2: 
Participant completes visits late in target 
windows
A. Participant completes first infusion on day 0 of week 0. 
The 4-week post visit window and next infusion window 
are created as described above.
B. Participant completes the post-infusion visit late in the 
visit window. Even though this visit is late in the 
window, the next infusion window is unaffected since it 
is the prior infusion date that sets the target.
C. Participant completes the second infusion at the end of 
the target window. The 5-day and 4-week post-infusion 
visit windows and the window for infusion #3 are 
created based on the date of the second infusion.
D. Participant completes the 5-day post-infusion visit late 
in the visit window; this does not affect the 4-week 
post-infusion window. Participant completes the 4-week 
post-infusion visit late in the window, and as above, the 
next infusion visit window is unaffected.
E. Participant completes the third infusion late in the 
target window, and the subsequent 4-week post-
infusion and next infusion visit windows are created 
based on the date of the third infusion.
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A. Ppt completes 1st infusion
Visit window est. from inf. #1 date
Visit window established from infusion #1 
dateInf 1
Week 0
4-wk post
Inf 2
B. Ppt completes 4-week post after 1st infusion
Visit window est. from inf. #1 date
Inf 1
Week 0
4-wk post
week 5
Inf 2
C. Ppt misses 2nd infusion
E. Ppt completes 4-week post after 3rd infusion
Scenario 3:
Participant misses one infusion
Visit window est. from inf. #1 date
Inf 2
Inf 1
Week 0
4-wk post
week 5
Visit window est. from date of missed visit form
Inf 3
After the first day of week 15, submit 
missed visit form with target date (week 8)
D. Ppt completes 3rd infusion
Inf 2
Inf 1
Week 0
4-wk post
week 5
Inf 3
week 18
(week 8 + 7 + 3)
Visit window est. from inf. #3 date
Inf 4
4-wk post
Visit window est. from inf. #3 date
4-wk post
week 5
Inf 2
week 9
Inf 3
week 18
4-wk post
week 14
Inf 1
Week 0
Visit window est. from inf. #3 date
Inf 4
4-wk post
week 22
(week 18 + 4)
Scale (study weeks):
0 4 8 12
Legend:
Infusion visit completed
Target infusion window
Allowable  infusion window
4-week post-infusion visit completed
4-week post –infusion visit window
5-day post-infusion visit completed
5-day post-infusion visit window
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Scenario 3: 
Participant misses one infusion
A. Participant completes first infusion and subsequent 
windows are created as described above.
B. Participant completes the 4-week post-infusion visit.
C. The participant does not come into the clinic during 
the open window for infusion #2.  The window 
closes, and because there was no infusion, no 5-day 
or 4-week post-infusion visit windows were created. 
To create the next infusion window, the site submits 
a missed visit form with the missed visit date 
reflecting the target date for that infusion.  
Submission of the missed visit form results in the 
creation of the visit window for the next infusion, 
infusion #3.
D. The participant comes in to complete infusion #3 
during the allowable window. This creates windows 
for both the 4-week post-infusion visit and the next 
infusion visit (#4) based on the date of infusion #3.
E. Participant completes the 4-week post-infusion visit 
from infusion #3 and the window for infusion #4 is 
unchanged.
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A. Ppt completes 1st infusion
Visit window est. from inf. #1 date
Visit window established from infusion #1 
dateInf 1
Week 0
4-wk post
Inf 2
B. Ppt completes 4-week post after 1st infusion
Visit window est. from inf. #1 date
Inf 1
Week 0
4-wk post
week 5
Inf 2
Scenario 4:
Participant misses two infusions
C. Ppt misses 2nd infusion
Visit window est. from inf. #1 date
Inf 2
Inf 1
Week 0
4-wk post
week 5
Visit window est. from date of missed visit form
Inf 3
After the first day of week 15, submit 
missed visit form with target date (week 8)
D. Ppt misses 3rd infusion
Inf 2
Inf 1
Week 0
4-wk post
week 5
Inf 4
Visit window est. from date of 
missed visit form
Inf 3
After the first day of week 23, submit 
missed visit form with target date (week 
16)
Visit window est. from inf. #1 date
Visit window est. from date of 
missed visit form
E. Ppt completes 4th infusion
Inf 2
Inf 1
Week 0
4-wk post
week 5
Visit window est. from date of 
missed visit form
Inf 3
Visit window est. from inf. #1 date
Inf 4
Week 26
(week 8 + 7  + 8 + 3)
Visit window est.
from inf. #4 date
4-wk post
Scale (study weeks):
0 4 8 12
Legend:
Infusion visit completed
Target infusion window
Allowable  infusion window
4-week post-infusion visit completed
4-week post –infusion visit window
5-day post-infusion visit completed
5-day post-infusion visit window
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Scenario 4: 
Participant misses two infusions
A. Participant completes first infusion and subsequent 
windows are created as described above.
B. Participant completes the 4-week post-infusion visit.
C. The participant does not come into the clinic during the 
open window for infusion #2. The window closes, and 
because there was no infusion, no 5-day or 4-week post-
infusion visit windows were created. The site submits a 
missed visit form to create the visit window for the next 
infusion, infusion #3.
D. The participant does not come into the clinic during the 
open window for infusion #3. Because there was no 
infusion, no 4-week post-infusion visit window was 
created. The window closes, and the site submits a 
missed visit form to create the visit window for the next 
infusion, infusion #4.
E. Participant completes 4th infusion in the allowable 
window.  This results in creation of the 4-week post-
infusion visit and the window for the next infusion visit 
(off page).
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